Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial

17 Oct 2026 0 comments

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Source: NeurologyLive · Published 15 Oct 2026 · Imported 17 Oct 2026

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment